readthroughSign in
Nov 16, 2026Regulatory decision

FDA approves AstraZeneca's Imfinzi with enfortumab vedotin for bladder cancer

The combination regimen is approved for muscle-invasive bladder cancer patients who cannot receive cisplatin-based chemotherapy, based on Phase III VOLGA trial results.

AstraZeneca said on 16 November 2026 that the FDA approved Imfinzi (durvalumab) in combination with enfortumab vedotin (EV) as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment after radical cystectomy, for adult patients with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy.1 The approval followed Priority Review and was based on results from the VOLGA Phase III trial, which were presented at a Presidential Symposium at the 2026 European Society for Medical Oncology Congress and simultaneously published in The New England Journal of Medicine.1

In the trial, patients received three cycles of Imfinzi and EV before radical cystectomy, followed by nine cycles of Imfinzi adjuvant monotherapy.1 An interim analysis showed the regimen cut the risk of disease progression, recurrence, failure to undergo surgery, or death by 49%, with a hazard ratio of 0.51 (95% CI 0.38-0.67, p<0.0001) versus radical cystectomy with or without approved adjuvant treatment.1 Estimated median event-free survival was not yet reached for the Imfinzi combination versus 12.1 months for the comparator arm, with an estimated 64% of patients on the combination alive and event-free at two years compared to 45% on the comparator.1

On the key secondary endpoint of overall survival, the combination lowered the risk of death by 42%, with a hazard ratio of 0.58 (95% CI 0.40-0.83, p=0.0027).1 Estimated median overall survival was not yet reached in either arm, and an estimated 78% of patients on the Imfinzi combination were alive at two years compared with 69% on the comparator.1

Safety was described as consistent with the known profiles of the individual medicines, with no new safety signals identified; Grade 3 and 4 adverse events occurred in 64% of patients on the combination versus 44% on the comparator.1 Regulatory applications based on VOLGA are under review in the European Union, Japan and other countries.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.